Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12257626 | 0.95 | DPP7 (0.34) | SLC18A3DPP7L3MBTL1 | |
| SCHEMBL2603332 | 0.91 | SLC18A3 (0.32) | SLC18A3CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL13910227 | 0.91 | SLC18A3 (0.32) | SLC18A3ALDH1A1 | |
| SCHEMBL2603339 | 0.91 | SLC18A3 (0.32) | SLC18A3CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL2603338 | 0.91 | SLC18A3 (0.32) | SLC18A3CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL13910189 | 0.91 | SLC18A3 (0.32) | SLC18A3CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL11947594 | 0.89 | SLC18A3 (0.35) | SLC18A3CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL13910203 | 0.89 | SLC18A3 (0.35) | SLC18A3CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL13910193 | 0.89 | SLC18A3 (0.35) | SLC18A3CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL11947597 | 0.89 | SLC18A3 (0.35) | SLC18A3CYP2D6MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024011155-A1 | OXAZOLE TRPML1 AGONISTS AND USES THEREOF | LIBRA THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-25 | — | — | US | disclosed |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-09-01 | — | — | US | disclosed |
| US-10654884-B2 | Purine derivatives as CD73 inhibitors for the treatment of cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-05-19 | — | — | US | disclosed |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC | 2019-11-14 | — | — | US | disclosed |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-09-05 | — | — | US | disclosed |
| US-10258624-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-04-16 | — | — | US | disclosed |
| US-8703810-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140107095-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8569264-B2 | Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents | ISIS PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130137746-A1 | INDANE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130116232-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130005674-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ISIS PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8114856-B2 | Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents | ISIS PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110166334-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ISIS PHARMACEUTICALS,INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-7893039-B2 | Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents | ISIS PHARMACEUTICALS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20080293649-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ISIS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166334-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ALG8, MRPL21, AADAC | SLC18A3 4761/4885CYP2D6 1003/4885MEN1 3404/4885 |
| US-10654884-B2 | Purine derivatives as CD73 inhibitors for the treatment of cancer | ENTPD5, NT5E, ENTPD1 | SLC18A3 467/4885CYP2D6 1720/4885MEN1 2222/4885 |
| US-20080293649-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ALG8, MRPL21, AADAC | SLC18A3 4761/4885CYP2D6 1003/4885MEN1 3404/4885 |
| US-20130005674-A1 | ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS | ALG8, MRPL21, AADAC | SLC18A3 4761/4885CYP2D6 1003/4885MEN1 3404/4885 |
| US-20130116232-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | SLC18A3 2117/4885CYP2D6 836/4885MEN1 4454/4885 |
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | SLC18A3 895/4885CYP2D6 2230/4885MEN1 3630/4885 |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | CXCR3, CXCR1, CCR7 | SLC18A3 895/4885CYP2D6 2230/4885MEN1 3630/4885 |
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | SLC18A3 950/4885CYP2D6 3373/4885MEN1 4405/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | SLC18A3 950/4885CYP2D6 3373/4885MEN1 4405/4885 |
| US-20140107095-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | SLC18A3 2023/4885CYP2D6 869/4885MEN1 4457/4885 |
| US-10258624-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | SLC18A3 950/4885CYP2D6 3373/4885MEN1 4405/4885 |
| US-20130137746-A1 | INDANE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GPER1, ESR2, ESR1 | SLC18A3 1199/4885CYP2D6 600/4885MEN1 4079/4885 |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | SLC18A3 950/4885CYP2D6 3373/4885MEN1 4405/4885 |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | SLC18A3 950/4885CYP2D6 3373/4885MEN1 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.